# 바이오스페이스 일일 뉴스 리포트 - 2026년 02월 07일


## 주요 헤드라인

1. **AbbVie CSO Touts ‘Breakthrough Type Therapy’ Psychedelic as J&J’s Spravato Keeps Growing (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/abbvie-cso-touts-breakthrough-type-therapy-psychedelic-as-j-js-spravato-keeps-growing>

2. **AbbVie CSO Touts ‘Breakthrough Type Therapy’ Psychedelic as J&J’s Spravato Keeps Growing (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/abbvie-cso-touts-breakthrough-type-therapy-psychedelic-as-j-js-spravato-keeps-growing>

3. **Biogen’s ‘Bridge To Growth’ Cuts Through a Stacked Phase 3 Pipeline (#뉴스)**
   - Article content not available
   <https://www.biospace.com/business/biogens-bridge-to-growth-cuts-through-a-stacked-phase-3-pipeline>

4. **Biogen’s ‘Bridge To Growth’ Cuts Through a Stacked Phase 3 Pipeline (#뉴스)**
   - Article content not available
   <https://www.biospace.com/business/biogens-bridge-to-growth-cuts-through-a-stacked-phase-3-pipeline>

5. **IPO Tracker 2026 (#뉴스)**
   - Article content not available
   <https://www.biospace.com/business/ipo-tracker-2026-eikon-clocks-largest-ipo-since-2024-generate-follows-as-ipo-tap-opens>

6. **IPO Tracker 2026 (#뉴스)**
   - Article content not available
   <https://www.biospace.com/business/ipo-tracker-2026-eikon-clocks-largest-ipo-since-2024-generate-follows-as-ipo-tap-opens>

7. **Priovant Plots Path to Phase 3 as Brepocitinib Clears Mid-Stage Skin Disease Study (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/priovant-plots-path-to-phase-3-as-brepocitinib-clears-mid-stage-skin-disease-study>


---
*2026년 02월 07일 바이오스페이스 뉴스 피드에서 생성된 리포트*